The Economist’s 8th Annual World Cancer Series: Europe convenes a wide range of stakeholders critical to effective cancer care, to drive innovation, equity and excellence
We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati
European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.
A $14 million research project is getting underway in the US to see whether cancer and other diseases can be diagnosed by picking up subtle changes in a person's voice patterns.
